Black Diamond Therapeutics, Inc. (BDTX) Tops Q1 EPS by 93c

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) reported Q1 EPS of $0.98, $0.93 better than the analyst estimate of $0.05. Revenue for the quarter came in at $70 million versus the consensus estimate of $28 million.

For earnings history and earnings-related data on Black Diamond Therapeutics, Inc. (BDTX) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• CACI wins U.S. Space Force contract worth up to $981M
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low